Related Experiment Video

Updated: Feb 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Galectin-3 in patients with coronary heart disease and atrial fibrillation

Qi Kang1, XiaoLong Li1, Mengyun Yang1

  • 1Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|December 31, 2017
PubMed

Insights

Galectin-3, an inflammatory marker, is elevated in severe coronary heart disease and negatively correlates with cardiac function. Its levels did not significantly change after treatment for acute myocardial infarction or atrial fibrillation ablation.

Area of Science:

  • Cardiology
  • Biomarkers
  • Inflammation

Background:

  • Coronary heart disease (CHD) involves inflammation and fibrosis.
  • Galectin-3 is implicated as an inflammatory mediator in cardiovascular diseases.
  • Understanding Galectin-3's role in CHD severity and treatment response is crucial.

Purpose of the Study:

  • To assess Galectin-3 levels in relation to coronary heart disease (CHD) severity.
  • To investigate Galectin-3 changes in atrial fibrillation (AF) post-radiofrequency ablation (RFCA).
  • To evaluate Galectin-3 response to high-dose atorvastatin in acute myocardial infarction (AMI).

Main Methods:

  • Enrolled patients with CHD and AF.
  • Administered high-dose atorvastatin (80mg) to AMI patients before PCI.
  • Utilized ELISA to measure Galectin-3 levels before and after RFCA in AF patients.

Main Results:

  • Galectin-3 levels were significantly higher in AMI and unstable angina pectoris (UAP) groups compared to stable angina pectoris (SAP).
  • Multivessel coronary disease showed higher Galectin-3 than single-vessel disease (P<0.05).
  • No significant Galectin-3 decrease was observed post-PCI in AMI or post-RFCA in AF patients.

Conclusions:

  • Galectin-3 is linked to myocardial inflammation, fibrosis, and ischemia severity.
  • Galectin-3 levels correlate negatively with left ventricular ejection fraction (LVEF).
  • The study suggests Galectin-3's association with CHD severity but limited acute treatment response.
Abstract

Keywords:
Atrial fibrillationCoronary heart diseaseGalectin-3

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

2.2K

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.1K
Amyloid Fibrils03:03

Amyloid Fibrils

6.5K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.2K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
553
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
307
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
572